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ABSTRACT 
Direct-To-Consumer (DTC) Advertising, the advertising of prescription and over-
the-counter drugs, has been controversial since its debut. Those who support it say that 
consumers have a right and even a need to know. Those opposing believe DTC ads are a 
way for pharmaceutical companies to make more money. This paper looks at the 
advantages and disadvantages of DTC advertising on patients, physicians and 
pharmaceutical companies and the turbulent atmosphere surrounding the controversy. 
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Background 
While many Americans will admit that our country has put too much faith in the 
medical field, most Americans do not realize how good we have gotten at swallowing 
pills. America spends more money on healthcare than any other country in the world. In 
fact, we spent "$1.8 trillion, more than 15% ofGDP [in 2004]" (Emmott 73). America 
"accounted for more than 40% of the world's $550 billion pharmaceutical market" 
(Emmott 73) in 2004. 
With all this emphasis on healthcare, pharmaceutical companies would be remiss 
if they didn't find a way to exploit it. And they have been for years. Direct-To-Consumer 
(DTC) advertising, or the advertising of prescription and over-the-counter drugs, has 
been around for longer than most people realize. Since the days of Vitam eat ave gamin, we 
have been bombarded with herbal remedies and tonics. In the 1980s, the Food and Drug 
Administration (FDA) began allowing pharmaceutical companies to advertise their 
prescription drugs in magazines and newspapers. A 1997 draft guidance by the FDA 
"relinquished a measure of its control over pharmaceutical companies' advertising 
strategies" (Lenhardt 165) and finally allowed the industry to advertise on TV, making 
America only the second country in the world to do so. "The United States and New 
Zealand are the only countries that allow pharmaceutical companies to pitch directly to 
consumers" (Quema 52). 
Today, DTC ads clutter those shows with a distinctly "adult" audience, such as 
"Jeopardy!" and the news. In fact, "DTC ads account for nearly a third of the advertising 
on the major broadcast networks' nightly news programs" (Thomaselli, et. at. 52). 
Anyone can watch a half hour "Jeopardy!" show and see advertisements for at least five 
different drugs. 
The Facts About DTC 
According to the Pharmaceutical Research and Manufacturers of America 
(PhRMA), DTC ads are only used for a few therapeutic drug categories: 1) those for 
diseases where the symptoms are easily recognizable, such as arthritis, seasonal allergies 
and obesity; 2) those for chronic diseases, such as cholesterol, osteoporosis and 
depression; and 3) those that enhance the quality oflife, such as for skin conditions, hair-
loss and erectile dysfunction. 
Pharmaceutical companies have the right "to communicate their marketing 
messages because these messages are protected as commercial speech" (Lenhardt 174) 
under the First Amendment. The basis for the protection is that the companies have a 
right to advertise and the public has a right to receive advertising (Lenhardt 175). The 
only "restrictions on commercial speech exist when the outcome of the speech can be 
harmful to the public" (Centor 12A). The obvious example is the tobacco industry. The 
Federal Communications Commission (FCC) restricted tobacco companies' rights to 
advertise because of the impact of the advertising on children. 
In order to restrict commercial speech, the speech in question first must pass the 
Central Hudson Test, a four part test meant to protect commercial speech. In the Central 
Hudson Test, 1) the speech must concern lawful activity and must not be misleadillg; 2) 
the government interest in regulating the speech must be substantial; 3) regulation of the 
speech must directly advance the government interest asserted; and 4) regulation mm,t be 
no more extensive than necessary to serve the interest asserted. For example, the tobacco 
industry's advertising concerned lawful activity because smoking is not against the law. 
The government had a substantial interest in regulating tobacco advertising because 
children were smoking in record numbers. Regulating the advertising served the 
government interest because less advertising resulted in fewer children smoking. Finally, 
the regulation was no more extensive than necessary because it still allowed tobacco 
companies to advertise in print and away from schools and parks. Until all four parts are 
met, restriction of the commercial speech in question is illegal. 
FDA Regulations 
If the commercial speech is legal, it is still subject to the FDA. The FDA requires 
all DTC advertising information: 
• To be accurate and not misleading; 
• To make claims only when supported by substantial evidence; 
• To reflect balance between risks and benefits; and 
• To be consistent with the FDA-approved labeling. 
The FDA does not have to review a DTC advertisement prior to broadcast unless 
the drug company requests a review; most review is made post hoc. If an advertisement is 
found to be offensive, the FDA can send cease-and-desist orders or warning letters or it 
can order remedial advertising to correct any misrepresentations. The FDA does not have 
the authority to fine drug companies. Though it seems that the FDA has no responsibility 
to the pharmaceutical companies, they are under pressure, too. Drug approvals are funded 
by the pharmaceutical industry, which exerts pressure on the FDA to push new drugs 
through. In 2002, the FDA approved 18 new drugs. In 2004, that number nearly doubled 
to 34, causing many to wonder about the safety of the drugs and the care taken by the 
FDA. 
Advantages of DTC 
DTC ads do have their advantages to pharmaceutical companies, physicians and 
patients. For pharmaceutical companies, the obvious advantage is income. However, 
beneath the surface, pharmaceutical companies are also concerned with compliance 
problems. "Half of all people with a chronic illness take themselves off their prescription 
medicines within the first 90 days of treatment," (Bittar 24) making it difficult to get post 
experimental results for the drugs. DTC ads can be used as a reminder for patients to stay 
on their prescriptions, thereby allowing pharmaceutical companies to gather results. 
Physicians benefit from DTC ads because they can save time. If patients come 
into the doctor's office with a sound body of knowledge about a drug, the doctor has to 
spend less time discussing the risks and benefits of the drug. This gives more time to 
diagnosis and discussion of symptoms. Doctors also benefit from patient compliance. 
When patients take themselves off medication, the doctor is usually not informed, 
creating a chasm when an emergency rises. If patients are encouraged by DTC ads to stay 
on their medicines, doctors won't be surprised later. 
For patients, the most often quoted advantage is information. Patients used to take 
the word of their doctors as gospel, not just on available drugs, but also on alternative 
therapies and the symptoms of the diseases themselves. With DTC ads on every 
television channel and in every magazine, patients are " 'more educated and they're 
going into their doctors' offices and asking questions,'" (Arnold 106). DTC ads have also 
been widely credited with getting people into their doctors' offices sooner than they 
might have otherwise gone. For example, "ads for Viagra persuaded millions of men to 
see their doctors. And when men went in to get their little blue pills, thousands were 
diagnosed with other conditions such as heart disease or diabetes" (Querna 52). In 
general, DTC ads have made patients more involved in their healthcare. 
Often overlooked is the price advantage of DTC advertising. While many believe 
that pharmaceutical advertising raises the price of prescription drugs, it was found several 
years ago that "prices of eyeglasses were twenty dollars higher (in 1963 dollars) in states 
banning advertising than in those that did not" (McBride 1). Advertising creates 
competition which brings in dollars. With more money coming in from sales, prescription 
costs are able to decrease. 
A final advantage ofDTC advertising is that "[it] may help to remove the stigma 
associated with mental impairment" (Lenhardt 184) and other so called taboo diseases, 
such as STDs. Many people are afraid to talk to their doctors about or receive 
prescriptions for depression, STDs or impotence. With DTC advertising, the diseases are 
widely known and talked about and, therefore, less taboo than they once were (See 
Appendix A). 
Disadvantages of DTC 
While it may seem that DTC advertising is good for all parties, the disadvantages 
seem to outweigh the advantages. The most often discussed disadvantage of DTC 
advertising is that it gives the impression that the advertised drug works better than it 
really does. "About seventy-five percent of physicians reported that their understanding 
of DTC ads is that they cause patients to overestimate the efficacy of the drugs 
advertised" (Lenhardt 187). Senate Majority Leader Bill Frist has become a forerunner in 
the fight to abolish DTC advertising. In a speech on July 1, he said "This ... advertising 
can oversell hope. It could oversell results. And it can also undersell the risk." Frist has 
called for a two year moratorium on advertising new prescription drugs. This is widely 
acknowledged by legislators to be a smart move because "most drugs that are withdrawn 
[from the market] for safety reasons are withdrawn in the first three years of marketing" 
(Mitchell 5). 
Another disadvantage of DTC advertising for both patients and doctors is that 
patients are diagnosing and prescribing for themselves. A recent Diflucan ad said, "I dare 
you to call your doctor." With an outright dare, patients are being told that they have 
every right to demand a drug. In a perfect world, DTC advertising'S problems could be 
mitigated by physicians explaining the risks and benefits to patients. But that just won't 
happen. Physicians are pressed for time, and they "must decide whether to have a lengthy 
discussion or take the course ofleast resistance" (Centor 12A) and prescribe the drug 
being requested. Research shows that "8.5 million Americans each year request 
prescriptions based on the content of DTCA campaigns" (Lenhardt 166). And many 
doctors are prescribing more drugs than ever; "from 1994 to 2001, the number [of 
prescriptions] increased by 50 percent. And now it's going up by 3 to 5 percent each 
year" (Trebilcock 67). This increase in prescription drug use has prompted the name 
Generation RX. 
Doctors can be swayed by the advertising, even when patients do not request a 
certain drug. DTC advertising caused the market for Vioxx to expand quickly, and 
patients for whom it was not intended began taking the drug in volume. "Physicians 
should have prescribed Vioxx only when a patient had gastric side effects from older, less 
expensive arthritis drugs" (Centor 12A). However, too many doctors and patients were 
convinced by the advertisements to try the drug, and they relied on the advertisements for 
all of their information gathering. Drug maker Merck was forced to withdraw Vioxx from 
the market in September 2004 after it was found to double the risk of heart attack and 
stroke. By this time, it was too late. Merck now faces thousands of lawsuits from Vioxx 
users and their survivors. 
Once the physician prescribes the drug, the real problems begin. Especially for 
those who don't really need the drug, prescription drug abuse increases with DTC 
advertising. From 2004 to 2005, "the number of people in the U.S. abusing prescription 
drugs, including painkillers, depressants and stimulants, increased from 7.8 million to 
15.1 million" (Metzler 24). DTC ads make prescription drug abuse worse because "they 
convince people that medicine can help them enjoy life more" (Querna 52). The ads seem 
"to imply that huge proportions of the population need pharmaceutical intervention for 
relatively common problems" (Lenhardt 198). 
The volume of drugs being prescribed has taken a toll on pharmacies as well. 
"The average pharmacy makes four errors for every 250 prescriptions that go out the door 
... That's only 1.6 percent, but apply that error rate to the more than three billion 
prescriptions dispensed a year, and the number of mistakes comes out to more than 50 
million" (Trebilcock 67). Pharmacy errors can be as simple as a wrong address, but the 
more serious mistakes could be much more costly. The FDA "recently issued a warning 
about errors that have occurred involving Zyprexa (a drug prescribed for schizophrenia 
and bipolar disorder) and Zyrtec, an antihistamine" (Trebilcock 68). When pharmacists 
are too busy, these two drugs can be easily switched. 
Finally, DTC ads are criticized for how they convey information. Many ads rush 
through the risks to get to the benefits. The language used to convey risks is above most 
Americans heads; "only a minority of Americans read at a level that would allow 
comprehension of [the] information" (Lenhardt 191). This is a disadvantage to not only 
the patient but also to the pharmaceutical companies because it creates bad publicity for 
them. They spend millions on something that makes them look bad. 
The Advertising 
Despite the bad publicity, pharmaceutical companies have been spending more 
and more on DTC advertising. Before Vioxx and Celebrex were taken off the market, 
Merck and Pfizer spent a collective $238 million on advertising those two drugs in 2000. 
In 2004, AstraZeneca spent $242 million on Nexium's advertising alone, making Nexium 
the 58th most heavily advertised brand in the United States and the most heavily 
advertised of the 34 drug brands in the top 200 advertised brands. (Donaton, Special 
Report S2). And mass media advertising isn't the only place that the pharmaceutical 
industry is spending its marketing dollars. Companies employ thousands of salesmen to 
market to doctors and pharmacists. "Pfizer ... employs more than 10% of America's sales 
reps" (Emmott 73). 
All of this spending is worth it to the pharmaceutical companies because of the 
volume of people reached by the advertising. "If every patient on a $2 billion 
cardiovascular medicine took just one additional pill each day, that would represent $17 
million in new revenue" (Bittar 24). And the advertising is working. "From 1999 to 2000, 
prescriptions written for the top 50 most heavily advertised drugs rose 24.6 percent, 
compared to 4.3 percent for all other drugs combined" (Marketing 1). DTC advertising 
has obviously affected which drugs physicians chose to prescribe. 
Recent changes to DTC advertising have added fuel to the fire. Drug companies 
have begun to broadcast disease awareness ads that focus on informing the public without 
touting the company's drugs. While these efforts may seem like a worthy attempt, many 
consumers believe that the pharmaceutical companies are just trying to change the 
public's perception of the companies without changing the way they do business. 
Consumer Reactions 
When the FDA began allowing DTC advertising, the public welcomed the new 
source of information. "In 1999, more than half of respondents to an FDA survey said 
they like seeing drug ads. In 2002, the number was less than a third" (Quema 52). More 
than half of those same respondents believed that there was not enough information about 
the risks and side effects. In a Wall Street Journal survey, more than half of respondents 
"said advertising should be banned when drugs are first sold so that doctors can learn 
about the products without being pressured by patients demanding prescriptions fur drugs 
they have seen advertised" (Henderson). 
In a survey I conducted (See Appendix B), respondents were given a list of 
prescription drug names found in television and print advertising and were asked first if 
they recognized the drug name. Then they were asked to write in the disease that the drug 
was used for. Out of fifteen drugs, the average respondent could recognize the name of 
9.1 drugs. However, they could only name the disease for an average of 4.9 drugs, 
showing that while DTC ads may break through the clutter, they still aren't making much 
of an impact. 
Some drugs were more likely to be recognized than others. One hundred percent 
of respondents recognized Lipitor, with 81 percent knowing that it treats high cholesterol. 
Fourteen percent recognized Topamax, with only 3 respondents knowing that it is for 
seizures and migraines. The most surprising find was that only 51 percent of respondents 
knew that Nexium (the purple pill) treats acid reflux. As noted earlier, Nexium is the 
most heavily advertised drug on the market. 
Next respondents were asked about the effect of DTC advertising on their 
opinions and practices. Thirty percent of respondents said that they had asked their 
doctors about an advertised drug. Of those that asked their doctors about a drug, a 
startling 82 percent received that drug, with 100 percent of men receiving the drug they 
asked for. Fifty-nine percent of respondents reported feeling rushed by their doctor 
during a visit, which accounts for some of the prescriptions. Though so many respondents 
discussed a drug with their doctors, 49 percent reported being annoyed by DTC ads, 
while only five felt well informed. 
Education seemed to have a drastic effect on how DTC ads were perceived. 
Seventy-five percent of respondents with a high school education felt that the 
pharmaceutical companies did a good job of balancing risks and benefits within 
advertisements; the number plummeted to 33 percent when asked of master's degree 
holders. Nearly the same results were true when respondents were asked if the FDA was 
careful and thorough when approving new drugs: 63 percent of high school graduates 
agreed while only 15 percent of college graduates agreed. As is clearly shown, 
advertising on "Jeopardy!" and the nightly news is effective at reaching those who 
already have a negative view of DTC advertising. 
Industry Reactions 
As consumers become more irate about DTC advertising, the pharmaceutical 
companies seem to give them more ammunition. "During the one month directly 
following [9/11], Pfizer spent twenty-five percent more on its Zoloft (depression) 
marketing campaigns than it had spent on promoting the product from January to June" 
(Lenhardt 195). The FDA has also begun to sit up and take notice. In 2003, the FDA sent 
five warning letters to pharmaceutical companies. In 2004, that number jumped to 13, 
and as of November 2, 2005, the FDA had sent 23 warning letters. 
After much unrest and the threat of legislation, the pharmaceutical industry seems 
to be trying to save face. Beginning with the cease-and-desist orders for Vioxx and 
Celebrex, some companies, such as Bristol-Squib Myers, began changing how they 
advertise. Bristol-Squib Myers imposed a moratorium that banned all advertising on new 
products for one year. Most other companies began with a falling off of advertisiIig 
spending. From January through May, DTC ad "spending was flat ... after eight 
consecutive years of soaring growth that included a 28% boost [in 2004] to $4.4 billion in 
measured media" (Thomaselli, Side Effects 1). Newspapers and magazines have even 
begun to notice fewer pharmaceutical pages. 
Besides advertising changes, Pfizer and others have begun loyalty programs, 
volume discounts, rebates and free trial offers. (See Appendix A) Pfizer Senior Vice 
President of U.S. Marketing, Greg Duncan said, "The right time to change is when you 
have the most momentum going." Though many consumers and lawmakers believe that it 
was a ploy to buy more time, PhRMA published a new code for DTC advertising on 
August 2, 2005. The code includes fifteen guiding principles to protect consumers while 
protecting the interests of the pharmaceutical companies. (See Appendix C) 
The principles call for all new ads to be shown to the FDA prior to broadcast, and 
for companies to include diet, lifestyle and disease awareness information and 
information for the uninsured and underinsured. The code bans the 15 second reminder 
ads that do not state risks and benefits and calls for all ads to be shown to age appropriate 
audiences. Though these seem to be steps in the right direction, the principles do not go 
into effect until January 1,2006, are strictly voluntary and can only be enforced through 
consumer action. 
Even for those that follow the guidelines, some consumers believe there is too 
much wiggle room. Principle 6, which calls for a variable moratorium on new drug 
advertising, leaves it up to the pharmaceutical company to determine what constitutes an 
"appropriate amount of time." PhRMA has explained that "establishing a single uniform 
waiting period for all companies and all medicines could have the unintended 
consequence of denying patients important information about new medicines, even after 
health care professionals have been well educated" (PhRMA 6). Principle 11 calls for all 
ads to be written in an understandable language, but there is no explanation of what 
reading level or languages must be included. Most consumers and lawmakers believe this 
just makes another loophole for pharmaceutical companies. "Letting the pharmaceutical 
industry regulate its own advertising is like 'the fox guarding the chicken coop,' said 
Democrat Henry Waxman of California" (Querna 52). 
In light of the principles, "Johnson & Johnson became the first company to create 
a more cautious, safety-oriented advertisement with more emphasis on drug risks and 
side-effects" (Horton, Reining In 1204). Other pharmaceutical companies and non-profit 
organizations have followed suit with disease awareness ads. (See Appendix A) Whether 
companies will continue to follow the PhRMA principles is yet to be seen, but for now, 
consumers are seeing many of the changes they have been waiting for. 
My Solution 
Clearly, there are fundamental problems with DTC advertising. Pharmaceutical 
companies assert that DTC ads help the public to stay informed and rely on more than 
just their doctors. But many consumers have a negative view ofDTC ads. Obviously, 
DTC advertising is not working the way pharmaceutical companies had hoped. It could 
be a powerful tool to keep the public informed, but current DTC ads are so bad at gaining 
attention and selling that many consumers block them out (See Appendix A). 
Of those who do pay attention to DTC ads, many survey respondents commented 
that the long list of side effects deters them from asking their doctors about the drug 
advertised. While this issue would have to be taken up with the FDA, some ofthe less 
obvious problems with DTC advertising could be fixed. 
To begin with, phannaceutical companies need to stop thinking of their products' 
end users as consumers; they are patients. And patients need to be treated differently than 
consumers. First of all, consumers buy products that help them work better, play better, 
or look better. Patients buy products that help them live better. If the brand of jeans that a 
consumer buys goes out of style, that consumer can go buy another pair of jeans. If a 
patient buys a medicine that gets taken off the market, that patient may have already 
suffered serious side effects, even death. Patients are vulnerable. They are a captive 
audience. Patients with serious health problems may be willing to try anything and 
pharmaceutical companies should be careful if only for this reason. 
Once phannaceutical companies begin to see their consumers in a different light, 
they need to try a different approach in order to reach them. Patients want to feel like 
someone cares about them. They don't like to feel out of control and DTC advertising 
could be just what the doctor ordered. Knowledge is power and patients would devour 
that knowledge if they only knew it was there. Instead of trying to tell a patient all of the 
possible side effects, benefits and reasons for taking the drug in 30 seconds, 
phannaceutical companies could direct patients to the Internet. Once there, patients could 
spend hours pouring over the infonnation. This approach would put the patients in the 
driver's seat. Phannaceutical companies could fill their Web sites with pages upon pages 
of infonnation, and patients who were really interested in the drug would take the time to 
look at it. Those who weren't interested in the drug would not be annoyed by the list of 
side effects rattled off to them during their favorite TV shows. 
Phannaceutical companies already do extensive research on the drugs they 
produce; they should understand the value of research to see what patients want in DTC 
advertising. Without research, pharmaceutical companies probably already know that 
patients don't want to be talked down to or confused. But do they realize that ads that 
show people mountain biking or kayaking don't convey the message that a drug works or 
is safe? (See Appendix A) Simple research told me that Lipitor was the most recognized 
drug on my survey. The ads for Lipitor don't show people relaxing and enjoying a 
leisurely time at the park; they show people who otherwise seem to be in good health 
who do a belly f10p in the water or run into a glass door because their high cholesterol is 
an unseen problem. These ads convey the message that even though you seem to be 
healthy, you should go to your doctor and check your cholesterol. Patients understand 
this. They relate to the message because they all think they are fine. 
The first and easiest way for pharmaceutical companies to learn what works in 
DTC ads is to see what drug is already doing well. Viagra's ads created a lot of buzz 
because they were the first to advertise about erectile dysfunction, but other drug ads 
seem to sell better because they do a good job. Relpax ads show a boulder crushing 
people at the most inopportune times to convey that a migraine can take you out fast. 
(See Appendix A) Compare that to the Topamax ads that show a mom and her son 
walking to school headache free. Which one gets the patients' attention? Obviously 
Relpax. Which one tells patients that they really need the drug? Relpax again. 
After seeing the difference between Topamax and Relpax, pharmaceutical 
companies should begin to make changes. The visuals and copy of DTC ads must be 
changed to fit the way patients think. DTC ads have to gain attention and hold it lcng 
enough to convey a message without boring those who don't want to hear the message. 
Conclusion 
Pharmaceutical companies have been advertising directly to consumers for years. 
But their efforts to inform the public are being undermined by the public's opinion of 
DTC ads. It will take a drastic change in the way they advertise for pharmaceutical 
companies to reach their audience. As long as patients dislike and ignore DTC 
advertising, their opinion of the ethics behind the advertising will be cynical. Once 
pharmaceutical companies begin to speak to patients in a language and manner that is 
acceptable to those patients, DTC advertising will become the public information tool 
that it was meant to be. Until then, the controversy will rage on. 
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APPENDIX A 
Ads such as this one help to remove the stigma associated with "taboo" diseases. 
More than 3.4 million American men 
experience some form of bladder condition. 
It"s a fact. Your chances of developing a mild bladder condition Increase after su ffering 
an illness or undergoing prostate surgery. Or maybe you find it's just the resu lt o! getting a 
little older. Serenity for MEN is an anatomica lly designed liner that fits comfortab:y in your briefs 
to provide disc reet protect ion. The Dry Fast Core'" locks in liquid quickly, while OdaSorb Plus" 
helps prevent odors. It"s the perfect solution to give you the confidence and freedom to keep on 
doing all the things you love to do. 
For a FREE sample, visit _w.serlnity.com/male 
Dr cIIi 1·8&&·299·8922 toll·lral 
20 
Many companies have begun prescription programs and discounted drug programs. 
: 
21 
Be part of a FREE program designed for NEXIUM users. 
Valuable savings, delicious recipes, advice from experts, helpful lifestyle lips, refill reminders-
we'll deliver all this and more righllo your door when you sign up for our free program. You 
see, we understand that you may want information about how to manage your condition wisely, 
and we want you 10 have it. So sign up today and get the help and support you deserve. 
To join, visit nexiumprogram.com, return the attached card, 
or call1·888-27·NEXIUM. 
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d· ase awareness ads. . I . es and medical associations have begun lse PharmaceutIca compam
YOur Skin has collected a lifetime of Sun 
memories . If you've see" a dermatologist 
about t hose rough, scaly, su,,-damaged 
spots 0" your head Or face called 
Acti"ic KeratosiS (AK>, you know there 
are probably more st i/l deve/opi"g . 
And that lef t untreated, AK could 
lead +0 serious Ski" problems. 
So Why wait? Call Or log 0" for your free 
Su" '" sk,,, I" formation Kit. You'll learn 
more about AK, a"d a prove" alt ernative 
to treat the AKs you See as well as t he 
ones nearby, still developIng underneath. 
Affer all, your Skin has memories. 
Let"s help keep t hem happy. 
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lmm )'OU can about OS 
Actinic Keratosis (AK). 
Call for your free 
Sun & S On Information Kit 
1-866 57 TREAT AI( 
(1 866-578 7328 J 
John Godleski died of heart disea~e. He was just two years old. A little boy. Imagine how his mom and dad died 
a little bit a~ well . Cardiova~cular disease is America's number two killer of children under 15. The American 
Heart Association ean help provide lifesaving information for your family. We have the research. We have the 
knowledge. Let us share it with you. 
,Im.,,.c.mh .. , ul u r ~ u r 1 UUH AHA ;t~22 American Heart . Association .. 
Learn and Live. 
Off~ good wh"~ supplies lase- Umit one per household. (12005. Ameriun Hurt Association. Inc. All rights rt':serwd. Unauthorized tlse prohlbltt:d. 
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I 
AfTER 20 YEARS OF HARD WORK WE'VE AU\MIrr; 
ELIM I NATED PEDIATRIC H 
ALMOST ISN'T OOD ENOUGH 
Today's medicines. Tomorrow's miracles :" 
• GlaxoSmithKline 
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Ads such as this one are bad at gaining and retaining the attention of the audience. 
People accept the fact that 
chemotherapy will cause nausea 
and vomiting. 
W find that unacc ptabl 
Stand up to it 
with the help of EMEND. 
Adding EMEND can help patient on ch m01herapies 
that are highly likely to ause nausea and vomiting. 
E ~END is a powerful mcdil:alion Ihal. 
\ hen slal1cd bcf(lre t'ach cvcl of 
chemOlherapy, can hdp prcv"enllhc nausea 
and vomiting caused b~ chcmotlltc'rapi s 
Ihal arc h ighly likd" 10 cause nausta 
and vorniling, EMEND wun..s wilh olher 
aminausea and vomiting mcdication' 
given by dO("lors at Ih~' lime (If 
chcm()thcrap~ In:atmenl. Adding I 
capsul .. t,r EME D .. ach day 101' 3 da\s 
can help adult pmients prcvcnL nausea 
.md vomiling for up to a full S days, 
Simply put , EME '0 may stop vour 
symptoms before thc~ stal1. 
Ask \,our doclor or nUl'l· aboul 
addi·ng EMEND, rOl' m I" infCllmatiun, 
\"isil www.standuptoit.com 
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IMPORTANTINFORMATION:EME~D 
i.- onl~ USt-d 10 help \'ll" '\~nt nausea 
and vOmilin!! caused h~ dleOlolherdP," 
II is not used 10 /'.el dJ 01 nausea and 
\'omiling ah..- the\ slm1, 
Tdl your doctor if nlU an: laking mlll'l 
mcdi in~s, iI HlII an- pn'!,rrl:lnl or plan 
10 h 'om< pr<'gnanl, or if \OU han- Ii\' 'r 
pJY')blcm~. EMEND mOl\" C;:llISl' ~,i<1l\s Iif<'-
threatening )~actj()ns if 1ISl.-d with cel1ain 
medicines. (. ee the scction "Who should 
not lake FMENO?" on Ihe adjacl'nl pagl', ) 
EME 0 rna\ alsu un '.:1 'illIll' 1l1\.'t1i illCS, 
induding chl'll1oth.:rnp\', l':lll>;ing Ilwm til 
work diflt'relllh in ,/lur hc)(h . Women 
who use birth control medicines during 
treatment with EMEND and ror up 10 
I month after using EMEND should also 
use a backup method of contraception 
to avoid pregnancy. 
rhe mosl comOl<tn silk ellC'cls 01 EMF n 
an: IiI dnl's>;, n<JUSC<.l, hic~'lIps, c',,"c;lipatioll , 
dialThea, and loS! of <JppelilC:. The .. e an: 
nol all Lhl' possibk side clk-c\. ' 01 EME 'D. 
EME D is il\ildablc b.\ PIl"Scriptlllll onl, 
Plca.~' I -ad 11ll' Pati 'nl Pmduct infOllllulion 
for EMEND Oil the ne I pa~w an discus" 
it \ ilh \,OUI tlOdOl. 
~ 
(aprep~ant) 
. , ,. 
Some phannaceutical companies have resorted to using celebrities to sell medications. 
ADDWLLKr 
• u. ........... Cor ..r.ty Ia _ :I) clilliclllIudia 
• AdM I .......... ADIII!IWL XI ..... 6S.,ar Wotaq of ....... _ 
root I'ar lbe oWt ollbe ....... .,. 
Ask ,.ur doctDr if ADDEIlALl D 
Is right for ,.. child • 
.. _-
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Ads that show healthy people in nature do not speak to the audience. 
30 
An antidepressant with a low risk of 
weight gain and sexual side effects? 
Yes! WELLBUTRIN XL. 
WEI..J..BlITRfN XL effectively treats depression with a low risk of weight gain and a low risk of sexual side effects. Clinical studies prove "-
Ask your doctDr about WB.1JJlJTRN XL. And ID find out more, visit www.wellbutrin-xl.com or call 1-800-366-2500. 
Experience Life. 
~ 
\Nell~~ X I:. 
bupropion Hel 
EXTENDED·RELEASE TABLETS 
visitwww.wellbutrin-xl.com and learn about a $70 savings 
Important information: WELLBUTRIN XL is not for everyone. There is a risk of seizure when taking WEUBUTRIN XL, so don't use if 
you've had a seizure or eating disorder, or if you abruptly stop using alcohol or sedatives. Don't take with MAOIs, or medicines that 
contain bupropion. When used with a nicotine patch or alone, there is a risk of increased blood pressure, sometimes severe. To reduce 
risk of serious side effects, tell your doctor if you have liver or kidney problems. Other side effects may include weight loss, dry mouth, 
nausea, difficulty sleeping, dizziness, or sore throat WELLBUTRIN XL is approved only for adults 18 years and OYer. In some children 
m teens, antidepressants increase suicidal thoughts or actions. Whether or not you are taking antidepressants, you or your family 
should call the doctor right away if you have worsening depression, thoughts of suicide, or sudden or severe changes in mood or 
behavior, especially at the beginning of treatment or after a change in dose (see Patient Information: What is Important InfrJrmatJon I 
should know and share with my family about taking antidepressants'!). 
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Ads such as these are good at breaking through the clutter and sticking in the audience's 
memory. 
RE PA 
BEC AU SE MIGRAINES 
H AVE T H EIR 
O WN AGENDA 
mallY things kllllC'k ) OU oul li kE' it mig-raill t·. 
10 )'1101'1. out migraine pain and S~OJptOlllS 
a~ nausea and Sl'n ith it)' Lo ligh t anti 
IIPopll' an' switchin~ to I\ l'lp"' . \flf'r 
clinical 'lutlip pro\(' that with Rl'lpilx. 
IM'IIpl.· gOI rel it·f \\ ilh just IInC' dOSt ' Ih,1I1 
laling itn iLrl'x , ,\ nd It \\orks fast. l or 
pl'tlple it slarL, to w urk ill 511 mi n utt's' 
gt't 001'1. to Lhl'i r day iJl two h our ... So don ' t 
migraint· ruin you r pft' C'lIlat ion, m pung or 
ollt.-r da". h k Your cioctor for it fr ( sam pip, 
1)111, Vllllr rln ..... r 1'111 dl~'ld. il 1\"II'<l' is fl~ht 1M \UII. I r 
YOII Ita\l' l·t·Main I)'I"'S "I 1 1<'" rl dlS<'a. ... · a IlIslnl") ,,' 
mul",. '11 <\, or Ilnrol1lmll 'II hh .. ..J PI' iSlIFI'. ,1\1 h,,"I'( 
lint lak!" H .. lpa , \ .. n r I'h, reMain 1" ~'l'h' 0""11 Stun'-
" ilh,"'1 llt'an dis,- So, lin\<' hllli "'noll 11I.H1 T/·I"Il·u 
pmLth-u",- Talk I') \nllr t1,,..wr Ir "flU h.I\'· risk la,'luf fur 
h,'an rli",'aw ,u!'it itS 'lI1okin~, high hl" .. d 11ft Uf. ' or 
high dwl"'l,'ml. .. r If \nu'n· pn 1(11.1111 lIr 11 II r-Ifl j!, 
HI·II''' ,hnul') nnl I .. , uSt-,1 "iUJiu al I'·.IM 72 hnllr> III 
tn'a'm"1l1 "'Ilt lh,' r"lIn" ill~ ""'<li,'ml'S: 'izrmtl , 
p"ranm, , So'rmll" • 1'\0 , fli,nill', 0" ir Hud \ Ira,,'p' , 
PIN«' ",' pa'"'111 MHtllllal" 01 inloTlllillion (lJ111I'~t I-W·. 
DON'T LET A MIGR AIN E KE EP YOU DOWN REI.PAX 
(eletnplan HBr) 
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APPENDIXB 
Prescription Drug Survey Results 
Surveys Collected 37 
A. Please indicate whether the name of the prescription drug on the left is familiar 
to you and then write in the disease that you believe it is supposed to alleviate. 
Nexium 
Celebrex 
Levitra 
Procrit 
Zyrtec 
Lipitor 
Zelnonn 
Zoloft 
Prilosec 
Topamax 
Actonel 
Ambien 
Humira 
Aricept 
Ditropan 
# Who Recognized Drug Name 
33 
34 
28 
25 
32 
37 
16 
29 
28 
5 
8 
21 
13 
8 
21 
# Who Knew Disease 
19 
20 
15 
9 
16 
30 
4 
19 
19 
3 
4 
12 
2 
4 
8 
Number who have taken one or more of these drugs 17 
B. Please answer the following questions honestly and to the best of your knowledge. 
1. Have you ever asked your doctor about a prescription drug after seeing an 
advertisement for it? 
YES NO 
11 26 
If yes, did you receive that prescription? 
YES 
9 
NO 
2 
2. Has a prescription drug advertisement ever convinced you to visit your doctor? 
YES NO 
1 36 
3. How does prescription drug advertising make you feel? 
well infonned 4 
34 
empowered 0 
angry 1 
annoyed 18 
indifferent 12 
other (please explain) 2 (worried, confused) 
4. Do you feel that prescription drug advertisements do a good job of explaining the risks 
and benefits of the drugs? 
YES NO 
16 20 
5. Do you feel that the FDA is careful and thorough when approving new drugs? 
YES NO Don't Know 
12 20 4 
If not, how could they improve? 
Be more forthcoming with all problems 1 
Fewer ads on market to make sure all are safe 1 
More time for testing 8 
Less pharmaceutical company influence on approval 2 
6. Have you ever felt rushed by your doctor during a visit? 
YES NO 
22 9 
7. Have you ever felt rushed by your pharmacist? 
8. Age 
9. Sex 
YES NO 
10 26 
30-39 12 
40-49 7 
50-59 13 
60-69 3 
70-79 2 
M 10 
F 27 
10. Education 
high school 8 
some college 8 
bachelor's degree 5 
master's degree 15 
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APPENDIXC 
PhRMA Guiding Principles 
1. These principles are premised on the recognition that DTC advertising of 
prescription medicines can benefit the public health by increasing awareness 
about diseases, educating patients about treatment options, motivating patients to 
contact their physicians and engage in a dialogue about health concerns, 
increasing the likelihood that patients will receive appropriate care for conditions 
that are frequently under-diagnosed and under-treated, and encouraging 
compliance with prescription drug treatment regimens. 
2. In accordance with FDA regulations, all DTC information should be accurate and 
not misleading, should make claims only when supported by substantial evidence, 
should reflect balance between risks and benefits, and should be consistent with 
FDA approved labeling. 
3. DTC advertising should be designed to responsibly educate the consumer about a 
prescription medicine and, where appropriate, the condition for which it may be 
prescribed. 
4. DTC advertising of prescription drugs should clearly indicate that the medicine is 
a prescription drug to distinguish such advertising from other advertising for non-
prescription products. 
5. DTC advertising should foster responsible communications between patients and 
health care professionals to help patients achieve better health and a more 
complete appreciation of both the health benefits and the known risks associated 
with the medicine being advertised. 
36 
6. Companies should spend an appropriate amount of time to educate health 
professionals about a new medicine or a new therapeutic indication before 
commencing the first DTC advertising campaign. 
7. Companies should responsibly alter or discontinue a DTC advertising campaign 
should new and reliable information indicate a serious previously unknown safety 
risk. 
8. Companies should submit all new DTC television advertisements to the FDA 
before releasing these advertisements for broadcast. 
9. DTC advertising should include information about the availability of other 
options such as diet and lifestyle changes where appropriate for the advertised 
condition. 
10. DTC television advertising that identifies a product by name should clearly state 
the health conditions for which the medicine is approved and the major risks 
associated with the medicine being advertised. 
11. DTC advertising should achieve a balanced presentation of both the benefits and 
the risks associated with the advertised prescription medicine. Furthermore, risks 
and safety information should be presented in clear, understandable language, 
without distraction from the content, and in a manner that supports the responsible 
dialogue between patients and health care professionals. 
12. All DTC advertising should respect the seriousness of the health conditions and 
the medicine being advertised. 
37 
13. In tenns of content and placement, DTC television and print advertisements 
should be targeted to avoid audiences that are not age appropriate for the 
messages involved. 
14. Companies are encouraged to promote health and disease awareness as part of 
their DTC advertising. 
15. Companies are encouraged to include infonnation in all DTC advertising, where 
feasible, about help for the uninsured and underinsured. (PhRMA, Guiding 
Principles) 
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